Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 273.44 USD -0.5%
Market Cap: 147B USD

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Amgen Inc

Revenue
32.5B USD
Cost of Revenue
-12.9B USD
Gross Profit
19.7B USD
Operating Expenses
-13.4B USD
Operating Income
6.2B USD
Other Expenses
-2B USD
Net Income
4.2B USD

Margins Comparison
Amgen Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Amgen Inc
NASDAQ:AMGN
147B USD
60%
19%
13%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
299B USD
67%
28%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
115.9B USD
78%
38%
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.3B USD
86%
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
130.4B AUD
52%
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.9B USD
87%
30%
34%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
XBRU:ARGX
37.2B EUR
89%
-15%
-5%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.3B USD
85%
-9%
-16%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Amgen Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Amgen Inc
NASDAQ:AMGN
147B USD
56%
5%
9%
10%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
299B USD
56%
4%
15%
11%
US
Gilead Sciences Inc
NASDAQ:GILD
115.9B USD
1%
0%
23%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.3B USD
-3%
-2%
24%
-80%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
130.4B AUD
16%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.9B USD
17%
13%
13%
16%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
37.2B EUR
-3%
-3%
-9%
-22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.3B USD
498%
-8%
-6%
-14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.